849035-92-3 Usage
Uses
Used in Pharmaceutical Industry:
Imidazo[1,2-c]pyrimidin-5(1H)-one is used as a pharmacological agent for its potential impact on the central nervous system, offering a foundation for the development of drugs targeting neurological conditions.
Used in Anticancer Research:
Imidazo[1,2-c]pyrimidin-5(1H)-one is utilized as an anticancer agent, being investigated for its potential to combat various types of cancer. Its specific role in cancer treatment is still under research, but its unique structure makes it a promising candidate for further development in oncology.
Used in Medicinal Chemistry Research:
Imidazo[1,2-c]pyrimidin-5(1H)-one serves as a chemical scaffold in drug design and development. Its structure is employed as a base for creating new compounds with therapeutic potential, particularly in the fields of central nervous system regulation and oncology.
Check Digit Verification of cas no
The CAS Registry Mumber 849035-92-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,4,9,0,3 and 5 respectively; the second part has 2 digits, 9 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 849035-92:
(8*8)+(7*4)+(6*9)+(5*0)+(4*3)+(3*5)+(2*9)+(1*2)=193
193 % 10 = 3
So 849035-92-3 is a valid CAS Registry Number.
849035-92-3Relevant academic research and scientific papers
Reigan, Philip,Gbaj, Abdul,Stratford, Ian J.,Bryce, Richard A.,Freeman, Sally
, p. 1248 - 1260 (2008)
Thymidine phosphorylase (TP) is over-expressed in various tumour types and plays an important role in tumour angiogenesis, growth, invasion and metastasis. The enzymatic activity of TP is required for the angiogenic effect of TP, therefore, inhibitors of TP are of significant interest in cancer chemotherapy. A series of xanthine oxidase (XO) activated prodrugs of known inhibitors of TP have been designed and synthesized with the ultimate intent of improving tumour selectivity and pharmacokinetic characteristics. These prodrugs were not inhibitors of TP, but were selectively oxidized by XO at C-2 and/or C-4 of the uracil ring moiety to generate the desired TP inhibitor. Molecular modelling of both the TP inhibitors and XO-activated prodrugs rationalized their binding in the active site of the human TP crystal structure.
